Pregnancy-specific 1l-glycoprotein (SP1) The pregnancy specific #1-glycoprotein (SP1) is synthesized by the human placenta and secreted into the maternal circulation. However, SP1 does not seem to be specific to pregnancy since it has been detected by radioimmunoassay in sera from 3 to 54% of healthy persons (Searle et al., 1978; Wurz, 1979; Tatarinov, 1980) and in sera from patients with a variety of malignant diseases, for instance 8-55% of breast cancer patients (Searle et al., 1978; Wiirz, 1979; Tatarinov, 1980) , depending on the detection limit of the assay. By means of a histological immunoperoxidase technique SP1 has been demonstrated in 37-76% of malignant tumours of the breast (Horne et al., 1976; Inaba et al., 1980; Walker, 1981) . Furthermore, the survival time was significantly longer for women with SP1 negative tumours than those with SP1 positive tumours (Horne et al., 1976) .
A prospective study (3 years) was undertaken to clarify the value of determining SP1 in serum taken preoperatively and/or detecting SP1 in tumour tissue as a prognostic indicator in the selection of patients with malignant breast tumours for chemotherapy.
The study comprised 113 women selected at random from patients admitted to the Department of Surgery during the course of about 6 months for investigation of and treatment for a suspected breast tumour. The histological classification was done as recommended by the WHO (Azzopardi et al., 1982) . Benign breast disease was found in 79 patients. The histological diagnoses were mammary dysplasia/fibrocystic disease (66 patients), fibroadenoma (5 patients), intraductal papilloma (5 patients), lipoma (2 patients), and phyllodes tumour (1 patient). Malignancy was histologically confirmed in 34 women, 7 of whom had previously had a contralateral malignant breast tumour, whereas breast cancer had previously not occurred Correspondence: S. Sorensen. Received 24 October 1983; accepted 17 January 1984. in the remaining. Twenty four of the latter were given a total mastectomy with partial axillary dissection and, depending on the histological findings, were treated postoperatively with radiotherapy and systemic adjuvant treatment (Andersen et al., 1981) . The other 3 patients had only the tumour removed because of age or a histological diagnosis of non-invasive ductal carcinoma. The seven patients with previous contralateral breast tumours weie given individual treatment. The patients with cancer were followed up for at least 3 years after operation.
The determination of SP1 in serum was performed with a highly sensitive radioimmunoassay described elsewhere (Sorensen and Trentemqller, 1983) . The assay consisted of standards, controls, unknown samples and controls for non-specific binding (NSB) of 1251-SP1 in standards and in all samples. As NSB of 1251-SPI for standards and samples was different (usually 7-8% and 5-6%, respectively) the percentage of binding for standards and samples was calculated by subtracting the corresponding NSB from antibody bound radioactivity and the total amount of radioactivity added, respectively. A spline function programme (Reinsch, 1967) The mean values were 1.3, 2.3 and 4.5 pg1-' and the coefficient of variation was 11.8-13.2% (n= 10-14). (Figure 3 ). Only one of 6 patients with positive SP1 staining in the tumour died from the breast cancer during the observation period of 3. years (Table I) .
The detection limit chosen does not include nonspecific interference (noise) (Hunter & Bennie, 1979) . When sera from subjects who might be expected to have little or no SP1 in the circulation were assayed, responses were close to the detection limit, but significant. Determinations of these samples in two dilutions seemed to display responses which were less steep than the corresponding part of the standard curve, Figure 1 (e, f). This might indicate non-specificity -although the values were derived from the upper more imprecise part of the curve -or presence of a minor SP1 component, SP1(y), (Sorensen & Trentemqller, 1983) . The non-specific reactivity may be large enough to obscure specific determinations, particularly at low levels (Hunter & Bennie, 1979) . However, a parallelism was found betweenr the standard curve and dilutions of serum samples with an SP1 concentration >2 pg 1- (Figure 1) .
A range for serum SP1 in women with benign breast tumour was obtained which agreed with that in healthy subjects (Kaminska et al., 1979; Wiirz, 1979; Rosen et al., 1982) . For patients with breast cancer the SP1 concentration was of the same level as that in women with benign tumours. No values above 3 pgl-1 were found which agreed with other studies (Bremmer et al., 1981; Rosen et al., 1982) , but conflicted with studies previously reported to have from 22% to 29% of SP1 determinations >>3ygl-' (Searle et al., 1978; Wurz, 1979) and 8% to 11% >l0pgI-' (Wiirz, 1979; Tatarinov, 1980) . In a less sensitive assay with a detection limit of lOpgl-1, SP1 was observed in only one of 42 patients with malignant breast disorders (Grudzinskas et al., 1980) . However, SP1 has been measured in the majority of homogenates of breast tumour tissue, both malignant and benign (Bremmer et al., 1981) although the concentrations measured were close to the detection limit.
By means of an indirect immunoperoxidase technique, SP1 was absent in all benign tumours except 4. Two of these had intraductal papillomatosis. In another study no benign tumours out of 12 were found to be SP1 positive (Home et al., 1976) . In malignant breast tumours SP1 was present in only 17% of the patients compared with 76, 53 and 37% in other studies (Horne et al., 1976; Inaba et al., 1980; Walker, 1981) . The explanation may be differences in the methods, the antisera, or the representativeness of the histological sections since SP1 positive cells are irregularly distributed in the tumour, or in the composition of the tumours. No correlation seems to exist between the intensity of SP1 staining in the tumour and the serum SP1 level. Strong SP1 positive tumours had normal serum SP1 concentration and vice versa. The significance of the degree of differentiation for the presence of SP1 is S. SQRENSEN et al. (Walker, 1981) , whereas homogenates of poorly differentiated carcinomas had a higher concentration of SP1 than those of well differentiated tumours (Bremmer et al., 1981) . The presence of SP1 in malignant tumours might indicate a shorter survival (Home et al., 1976) , but the low incidence of SP1 positive tumours and a follow-up period of only 3 years in this study meant that the number of patients was too small to permit satisfactory statistical analysis. Furthermore, various postoperative chemotherapeutic regimes may influence the survival.
In conclusion, quantification of SP1 in sera or an investigation for the presence of SP1 in tumour tissue seem to be of little clinical value in the management of patients with breast cancer. On the other hand, SP1 has been demonstrated in some breast cancers and it remains to be elucidated whether this detection indicates local production or an uptake of SP1 from the circulation. Finally, a study is required to determine whether the serum SP1 levels obtained are truly being assayed or arise from a matrix effect in the radioimmunoassay.
